Are Granules India Ltd latest results good or bad?

Granules India Ltd's latest financial results for Q4 FY26 reveal a strong operational performance characterized by significant growth in both revenue and net profit. The company reported net sales of ₹1,470.61 crores, reflecting a year-on-year increase of 22.81% and a quarter-on-quarter growth of 5.96%. This marks the highest quarterly revenue in the company's recent history, indicating robust demand across its product portfolio. Net profit for the quarter reached ₹201.57 crores, which represents a year-on-year increase of 32.59% and a quarter-on-quarter growth of 34.19%. The operating margin, excluding other income, expanded to 24.16%, up from 21.09% in the same quarter last year, showcasing enhanced operational efficiency and a favorable product mix. Granules India also demonstrated strong capital efficiency with a return on equity (ROE) of 15.81%, positioning it competitively within the pharmaceutical sector. The company's balance sheet remains solid, with a debt-to-EBITDA ratio of 1.41 times and a net debt-to-equity ratio of 0.30, providing ample room for growth investments. Despite these positive operational trends, the company experienced an adjustment in its evaluation, reflecting the market's perception of its valuation relative to its financial performance. The stock has shown exceptional performance over the past year, significantly outperforming the broader market index. In summary, Granules India Ltd's Q4 FY26 results highlight a strong operational momentum with impressive growth in revenue and profitability, alongside solid capital efficiency and a robust balance sheet, while also indicating a recent adjustment in its evaluation.